ImmCelz® Stem Cell Component Demonstrated Efficacious in FDA Double Blind Placebo Controlled Clinical Trial of Advanced COVID-19 Patients


PHOENIX, Jan. 6, 2021 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTC: CELZ) commented today on a peer-reviewed publication from the University of Miami demonstrating that the intravenous administration of umbilical cord derived stem cells, termed "JadiCells" results in a significant survival improvement in COVID-19 patients.

The Phase 1/2 double blind, placebo-controlled trial treated 12 advanced COVID-19 patients with 100 million JadiCells™ intravenously at days 0 and 3, and 12 additional patients received placebo control.  At 28 days 91% of JadiCell™ treated patients survived whereas only 42% of patients in the placebo group survived.  There were no adverse effects associated with JadiCell™ administration.

"The ImmCelz® regenerative immunotherapy product is a personalized cellular therapy generated by co-culture of patient's immune cells with stem cells.  Due to the superior nature of the JadiCell™ to other cell types, under license, we exclusively use this cell type for production of ImmCelz®," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. "The data reported today strongly supports the safety and potency of the JadiCell™, which also supports the validity of ImmCelz® which is 'powered by JadiCell™.' It should be noted that neither Creative Medical Technology Holdings nor ImmCelz® were involved in the University of Miami trial, and that Creative Medical Technology Holdings is not pursuing COVID-19 treatments at this time," Mr. Warbington said further.

The ImmCelz® cell therapy product has demonstrated efficacy in animal models of stroke, heart failure, autoimmunity, and liver failure.  While the majority of companies utilize stem cell administration for therapeutic intent, ImmCelz® uses stem cells to "reprogram" patient immune cells, a process which endows the immune cells with ability to regenerate injured organs.

"It has been my pleasure to work with Timothy Warbington and his scientific team in creating a new class of cellular therapies that combines regenerative medicine with immunotherapy," said Amit Patel, MD, MS, inventor of the JadiCell™ and co-inventor of ImmCelz®.  "The speed, precision and innovation that drives the team at Creative Medical Technology Holdings is unparalleled and I look forward to clinical translation of ImmCelz®, which is the subject of an Investigational New Drug Application that is being currently compiled."

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in regenerative stem cell technology in the fields of Immunotherapy, urology, neurology and orthopedics, and is quoted on the OTC Markets under the symbol CELZ. For further information about the company, please visit 

Forward Looking Statements

OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at



Cision View original content to download multimedia:

SOURCE Creative Medical Technology Holdings, Inc.


Back to news